CN107250145A - 被取代的核苷、核苷酸及其类似物 - Google Patents

被取代的核苷、核苷酸及其类似物 Download PDF

Info

Publication number: CN107250145A
Authority: CN; China
Prior art keywords: optionally substituted; alkyl; virus; compound according; hydrogen
Prior art date: 2014-12-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN201580076647.5A

Other languages

English (en)

Chinese (zh)

Inventor

王广义

D.B.史密斯

L.贝格曼

C.A.杰克勒

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Janssen Biopharma Inc

Original Assignee

Alios Biopharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-19

Filing date

2015-12-16

Publication date

2017-10-13

2015-12-16 Application filed by Alios Biopharma Inc filed Critical Alios Biopharma Inc

2017-10-13 Publication of CN107250145A publication Critical patent/CN107250145A/zh

Status Pending legal-status Critical Current

Links

239000002777 nucleoside Substances 0.000 title abstract description 21
125000003835 nucleoside group Chemical group 0.000 title abstract description 18
125000003729 nucleotide group Chemical group 0.000 title abstract description 10
239000002773 nucleotide Substances 0.000 title abstract description 5
238000000034 method Methods 0.000 claims abstract description 59
201000010099 disease Diseases 0.000 claims abstract description 23
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 23
208000005155 Picornaviridae Infections Diseases 0.000 claims abstract description 19
150000001875 compounds Chemical class 0.000 claims description 427
229910052739 hydrogen Inorganic materials 0.000 claims description 174
150000003839 salts Chemical class 0.000 claims description 172
239000001257 hydrogen Substances 0.000 claims description 171
-1 C1-6 Alkyl azide Chemical class 0.000 claims description 149
125000003118 aryl group Chemical group 0.000 claims description 114
125000000217 alkyl group Chemical group 0.000 claims description 103
241000700605 Viruses Species 0.000 claims description 91
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 89
150000002431 hydrogen Chemical class 0.000 claims description 72
125000001072 heteroaryl group Chemical group 0.000 claims description 67
241000709661 Enterovirus Species 0.000 claims description 55
241000709664 Picornaviridae Species 0.000 claims description 51
208000015181 infectious disease Diseases 0.000 claims description 48
150000001413 amino acids Chemical class 0.000 claims description 44
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 40
239000008194 pharmaceutical composition Substances 0.000 claims description 40
125000001424 substituent group Chemical group 0.000 claims description 39
239000003814 drug Substances 0.000 claims description 38
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 30
229910052805 deuterium Inorganic materials 0.000 claims description 27
229910052736 halogen Inorganic materials 0.000 claims description 24
229910052760 oxygen Inorganic materials 0.000 claims description 24
239000001301 oxygen Substances 0.000 claims description 23
241000709715 Hepatovirus Species 0.000 claims description 21
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 21
150000002367 halogens Chemical class 0.000 claims description 21
125000000304 alkynyl group Chemical group 0.000 claims description 20
125000000623 heterocyclic group Chemical group 0.000 claims description 20
239000000126 substance Substances 0.000 claims description 20
230000008859 change Effects 0.000 claims description 18
241001466953 Echovirus Species 0.000 claims description 16
230000003612 virological effect Effects 0.000 claims description 16
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 15
229910052698 phosphorus Inorganic materials 0.000 claims description 14
239000011574 phosphorus Substances 0.000 claims description 14
229940079593 drug Drugs 0.000 claims description 13
150000002148 esters Chemical class 0.000 claims description 13
125000001188 haloalkyl group Chemical group 0.000 claims description 13
125000003545 alkoxy group Chemical group 0.000 claims description 12
125000002252 acyl group Chemical group 0.000 claims description 11
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 10
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 9
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
239000002574 poison Substances 0.000 claims description 9
231100000614 poison Toxicity 0.000 claims description 9
125000003107 substituted aryl group Chemical group 0.000 claims description 9
241000710190 Cardiovirus Species 0.000 claims description 8
241000283073 Equus caballus Species 0.000 claims description 8
239000003085 diluting agent Substances 0.000 claims description 8
241000031976 Aquamavirus Species 0.000 claims description 7
241001632249 Cosavirus Species 0.000 claims description 7
241000031978 Dicipivirus Species 0.000 claims description 7
241000204855 Echovirus E1 Species 0.000 claims description 7
241000217440 Echovirus E3 Species 0.000 claims description 7
241001492209 Echovirus E4 Species 0.000 claims description 7
241000122140 Echovirus E5 Species 0.000 claims description 7
241000709638 Echovirus E6 Species 0.000 claims description 7
241000031979 Megrivirus Species 0.000 claims description 7
206010044565 Tremor Diseases 0.000 claims description 7
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 6
150000001540 azides Chemical class 0.000 claims description 6
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 5
241000988559 Enterovirus A Species 0.000 claims description 5
241001529459 Enterovirus A71 Species 0.000 claims description 5
241000988556 Enterovirus B Species 0.000 claims description 5
241000991586 Enterovirus D Species 0.000 claims description 5
241000709691 Enterovirus E Species 0.000 claims description 5
241000033076 Enterovirus F Species 0.000 claims description 5
241001523584 Enterovirus G Species 0.000 claims description 5
241001219115 Enterovirus H Species 0.000 claims description 5
241000033074 Enterovirus J Species 0.000 claims description 5
241001325464 Rhinovirus A Species 0.000 claims description 5
241001325459 Rhinovirus B Species 0.000 claims description 5
241001139982 Rhinovirus C Species 0.000 claims description 5
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 5
125000003277 amino group Chemical group 0.000 claims description 5
108020004707 nucleic acids Proteins 0.000 claims description 5
150000007523 nucleic acids Chemical class 0.000 claims description 5
102000039446 nucleic acids Human genes 0.000 claims description 5
239000000546 pharmaceutical excipient Substances 0.000 claims description 5
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
241000709721 Hepatovirus A Species 0.000 claims description 4
230000006872 improvement Effects 0.000 claims description 4
210000000936 intestine Anatomy 0.000 claims description 4
125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 3
241000146303 Coxsackievirus A1 Species 0.000 claims description 3
241000146367 Coxsackievirus A10 Species 0.000 claims description 3
241000146297 Coxsackievirus A11 Species 0.000 claims description 3
241000146296 Coxsackievirus A12 Species 0.000 claims description 3
241000146307 Coxsackievirus A13 Species 0.000 claims description 3
241000146306 Coxsackievirus A14 Species 0.000 claims description 3
241001429382 Coxsackievirus A16 Species 0.000 claims description 3
241000146309 Coxsackievirus A17 Species 0.000 claims description 3
241000146305 Coxsackievirus A19 Species 0.000 claims description 3
241001466951 Coxsackievirus A2 Species 0.000 claims description 3
241000709698 Coxsackievirus A21 Species 0.000 claims description 3
241000146325 Coxsackievirus A3 Species 0.000 claims description 3
241000146328 Coxsackievirus A4 Species 0.000 claims description 3
241000146327 Coxsackievirus A5 Species 0.000 claims description 3
241001669084 Coxsackievirus A6 Species 0.000 claims description 3
241000146321 Coxsackievirus A7 Species 0.000 claims description 3
241000146319 Coxsackievirus A8 Species 0.000 claims description 3
241000217429 Echovirus E13 Species 0.000 claims description 3
241000217413 Echovirus E14 Species 0.000 claims description 3
241000217417 Echovirus E16 Species 0.000 claims description 3
241000217419 Echovirus E17 Species 0.000 claims description 3
241000217421 Echovirus E18 Species 0.000 claims description 3
241000217425 Echovirus E20 Species 0.000 claims description 3
241000217427 Echovirus E21 Species 0.000 claims description 3
241000190163 Echovirus E25 Species 0.000 claims description 3
241000217449 Echovirus E26 Species 0.000 claims description 3
241000193778 Echovirus E27 Species 0.000 claims description 3
241000134257 Echovirus E30 Species 0.000 claims description 3
241000217434 Echovirus E31 Species 0.000 claims description 3
241000217438 Echovirus E33 Species 0.000 claims description 3
241000201383 Echovirus E7 Species 0.000 claims description 3
241000709643 Echovirus E9 Species 0.000 claims description 3
241000693328 Enterovirus B69 Species 0.000 claims description 3
241000146324 Enterovirus D68 Species 0.000 claims description 3
241000709701 Human poliovirus 1 Species 0.000 claims description 3
241000709727 Human poliovirus 3 Species 0.000 claims description 3
241001597008 Nomeidae Species 0.000 claims description 3
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
201000002491 encephalomyelitis Diseases 0.000 claims description 3
229910052717 sulfur Inorganic materials 0.000 claims description 2
241000217415 Echovirus E15 Species 0.000 claims 2
241000217448 Echovirus E24 Species 0.000 claims 2
241000217436 Echovirus E32 Species 0.000 claims 2
239000000890 drug combination Substances 0.000 claims 2
238000010189 synthetic method Methods 0.000 abstract description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 273
239000000243 solution Substances 0.000 description 241
239000000203 mixture Substances 0.000 description 211
239000007787 solid Substances 0.000 description 108
239000002585 base Substances 0.000 description 106
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 105
230000002829 reductive effect Effects 0.000 description 89
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 80
238000006243 chemical reaction Methods 0.000 description 67
239000012044 organic layer Substances 0.000 description 59
238000004440 column chromatography Methods 0.000 description 54
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 53
210000004027 cell Anatomy 0.000 description 53
239000007864 aqueous solution Substances 0.000 description 52
229940024606 amino acid Drugs 0.000 description 47
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 44
235000001014 amino acid Nutrition 0.000 description 44
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 43
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
229910052799 carbon Inorganic materials 0.000 description 42
238000001035 drying Methods 0.000 description 42
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 41
239000003795 chemical substances by application Substances 0.000 description 37
238000003756 stirring Methods 0.000 description 35
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 34
235000019439 ethyl acetate Nutrition 0.000 description 34
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 33
239000000741 silica gel Substances 0.000 description 32
229910002027 silica gel Inorganic materials 0.000 description 32
229960001866 silicon dioxide Drugs 0.000 description 32
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 30
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
239000000460 chlorine Substances 0.000 description 27
239000012043 crude product Substances 0.000 description 27
239000007832 Na2SO4 Substances 0.000 description 26
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 26
239000002253 acid Substances 0.000 description 26
230000000694 effects Effects 0.000 description 26
238000002360 preparation method Methods 0.000 description 26
229910052938 sodium sulfate Inorganic materials 0.000 description 26
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 25
239000003921 oil Substances 0.000 description 25
239000012071 phase Substances 0.000 description 25
239000012266 salt solution Substances 0.000 description 25
229960000549 4-dimethylaminophenol Drugs 0.000 description 22
125000003342 alkenyl group Chemical group 0.000 description 22
229910052796 boron Inorganic materials 0.000 description 22
238000005406 washing Methods 0.000 description 22
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 21
SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 21
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 20
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 20
125000000753 cycloalkyl group Chemical group 0.000 description 20
239000005864 Sulphur Substances 0.000 description 19
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 19
239000011734 sodium Substances 0.000 description 19
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 18
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 18
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
230000000903 blocking effect Effects 0.000 description 18
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 17
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
239000000706 filtrate Substances 0.000 description 16
238000000746 purification Methods 0.000 description 16
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 15
125000000392 cycloalkenyl group Chemical group 0.000 description 15
230000006837 decompression Effects 0.000 description 15
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 15
239000011780 sodium chloride Substances 0.000 description 15
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 15
238000013019 agitation Methods 0.000 description 14
235000019270 ammonium chloride Nutrition 0.000 description 14
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 14
238000002953 preparative HPLC Methods 0.000 description 14
229940002612 prodrug Drugs 0.000 description 14
239000000651 prodrug Substances 0.000 description 14
JAPYIBBSTJFDAK-UHFFFAOYSA-N 2,4,6-tri(propan-2-yl)benzenesulfonyl chloride Chemical class CC(C)C1=CC(C(C)C)=C(S(Cl)(=O)=O)C(C(C)C)=C1 JAPYIBBSTJFDAK-UHFFFAOYSA-N 0.000 description 13
241000709687 Coxsackievirus Species 0.000 description 13
239000001963 growth medium Substances 0.000 description 13
229940079322 interferon Drugs 0.000 description 13
229910052943 magnesium sulfate Inorganic materials 0.000 description 13
230000009467 reduction Effects 0.000 description 13
238000006722 reduction reaction Methods 0.000 description 13
229910000030 sodium bicarbonate Inorganic materials 0.000 description 13
208000024891 symptom Diseases 0.000 description 13
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
0 CCC1(C)C(CC)(CC)*CC1 Chemical compound CCC1(C)C(CC)(CC)*CC1 0.000 description 12
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
239000012141 concentrate Substances 0.000 description 12
150000002460 imidazoles Chemical class 0.000 description 12
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 12
229910021529 ammonia Inorganic materials 0.000 description 11
125000004429 atom Chemical group 0.000 description 11
150000001721 carbon Chemical group 0.000 description 11
108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
102000014150 Interferons Human genes 0.000 description 10
108010050904 Interferons Proteins 0.000 description 10
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
235000017557 sodium bicarbonate Nutrition 0.000 description 10
238000006467 substitution reaction Methods 0.000 description 10
230000001988 toxicity Effects 0.000 description 10
231100000419 toxicity Toxicity 0.000 description 10
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 9
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
239000004472 Lysine Substances 0.000 description 9
229910019142 PO4 Inorganic materials 0.000 description 9
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 9
NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 9
238000010828 elution Methods 0.000 description 9
208000005252 hepatitis A Diseases 0.000 description 9
239000007788 liquid Substances 0.000 description 9
229960003646 lysine Drugs 0.000 description 9
230000004048 modification Effects 0.000 description 9
238000012986 modification Methods 0.000 description 9
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 9
229910000069 nitrogen hydride Inorganic materials 0.000 description 9
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
239000010452 phosphate Substances 0.000 description 9
238000010926 purge Methods 0.000 description 9
BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 9
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 8
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 8
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
241001465754 Metazoa Species 0.000 description 8
229960003767 alanine Drugs 0.000 description 8
235000004279 alanine Nutrition 0.000 description 8
229910000147 aluminium phosphate Inorganic materials 0.000 description 8
239000003153 chemical reaction reagent Substances 0.000 description 8
239000011737 fluorine Substances 0.000 description 8
238000004128 high performance liquid chromatography Methods 0.000 description 8
230000000670 limiting effect Effects 0.000 description 8
229910052757 nitrogen Inorganic materials 0.000 description 8
239000002904 solvent Substances 0.000 description 8
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
238000006646 Dess-Martin oxidation reaction Methods 0.000 description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
239000004471 Glycine Substances 0.000 description 7
239000003513 alkali Substances 0.000 description 7
LDDQLRUQCUTJBB-UHFFFAOYSA-N ammonium fluoride Chemical compound [NH4+].[F-] LDDQLRUQCUTJBB-UHFFFAOYSA-N 0.000 description 7
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 7
125000004122 cyclic group Chemical group 0.000 description 7
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 7
238000001914 filtration Methods 0.000 description 7
229910052731 fluorine Inorganic materials 0.000 description 7
229960002449 glycine Drugs 0.000 description 7
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 7
239000007924 injection Substances 0.000 description 7
238000002347 injection Methods 0.000 description 7
235000019341 magnesium sulphate Nutrition 0.000 description 7
150000002972 pentoses Chemical group 0.000 description 7
239000002243 precursor Substances 0.000 description 7
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 6
241000196324 Embryophyta Species 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 6
125000002947 alkylene group Chemical group 0.000 description 6
235000012538 ammonium bicarbonate Nutrition 0.000 description 6
235000011114 ammonium hydroxide Nutrition 0.000 description 6
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical group NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 6
CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 6
239000000284 extract Substances 0.000 description 6
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
238000002156 mixing Methods 0.000 description 6
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
238000012545 processing Methods 0.000 description 6
239000000047 product Substances 0.000 description 6
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
238000010791 quenching Methods 0.000 description 6
230000000171 quenching effect Effects 0.000 description 6
230000004044 response Effects 0.000 description 6
229960004295 valine Drugs 0.000 description 6
239000004474 valine Substances 0.000 description 6
230000009385 viral infection Effects 0.000 description 6
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical class CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 5
YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 5
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 5
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 5
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 5
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 5
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 5
229930182555 Penicillin Natural products 0.000 description 5
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
239000004473 Threonine Substances 0.000 description 5
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
230000000840 anti-viral effect Effects 0.000 description 5
229960001230 asparagine Drugs 0.000 description 5
235000009582 asparagine Nutrition 0.000 description 5
229960005261 aspartic acid Drugs 0.000 description 5
235000003704 aspartic acid Nutrition 0.000 description 5
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 5
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 5
229910052801 chlorine Inorganic materials 0.000 description 5
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 5
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 5
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
229960002433 cysteine Drugs 0.000 description 5
235000018417 cysteine Nutrition 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
238000001704 evaporation Methods 0.000 description 5
235000019253 formic acid Nutrition 0.000 description 5
229960002989 glutamic acid Drugs 0.000 description 5
235000013922 glutamic acid Nutrition 0.000 description 5
239000004220 glutamic acid Substances 0.000 description 5
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
229960002743 glutamine Drugs 0.000 description 5
235000004554 glutamine Nutrition 0.000 description 5
125000005842 heteroatom Chemical group 0.000 description 5
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
229960002885 histidine Drugs 0.000 description 5
125000002768 hydroxyalkyl group Chemical group 0.000 description 5
229910052740 iodine Inorganic materials 0.000 description 5
239000011630 iodine Substances 0.000 description 5
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 5
229960000310 isoleucine Drugs 0.000 description 5
229960003136 leucine Drugs 0.000 description 5
229930182817 methionine Natural products 0.000 description 5
229960004452 methionine Drugs 0.000 description 5
125000001624 naphthyl group Chemical group 0.000 description 5
230000003472 neutralizing effect Effects 0.000 description 5
238000004806 packaging method and process Methods 0.000 description 5
229940049954 penicillin Drugs 0.000 description 5
230000008569 process Effects 0.000 description 5
229960002429 proline Drugs 0.000 description 5
229960001153 serine Drugs 0.000 description 5
238000010898 silica gel chromatography Methods 0.000 description 5
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 5
229960002898 threonine Drugs 0.000 description 5
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 5
229960004799 tryptophan Drugs 0.000 description 5
GQEZCXVZFLOKMC-UHFFFAOYSA-N 1-hexadecene Chemical compound CCCCCCCCCCCCCCC=C GQEZCXVZFLOKMC-UHFFFAOYSA-N 0.000 description 4
HFDVRLIODXPAHB-UHFFFAOYSA-N 1-tetradecene Chemical compound CCCCCCCCCCCCC=C HFDVRLIODXPAHB-UHFFFAOYSA-N 0.000 description 4
OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 4
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
229930024421 Adenine Natural products 0.000 description 4
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 4
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 4
239000004475 Arginine Substances 0.000 description 4
241000991587 Enterovirus C Species 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 4
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
229960000643 adenine Drugs 0.000 description 4
125000004414 alkyl thio group Chemical group 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
239000001099 ammonium carbonate Substances 0.000 description 4
239000000908 ammonium hydroxide Substances 0.000 description 4
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
229960003121 arginine Drugs 0.000 description 4
150000003851 azoles Chemical class 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000033228 biological regulation Effects 0.000 description 4
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 4
230000000875 corresponding effect Effects 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
230000002255 enzymatic effect Effects 0.000 description 4
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
125000001183 hydrocarbyl group Chemical group 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 4
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
125000002950 monocyclic group Chemical group 0.000 description 4
230000003647 oxidation Effects 0.000 description 4
238000007254 oxidation reaction Methods 0.000 description 4
230000001590 oxidative effect Effects 0.000 description 4
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
229960005190 phenylalanine Drugs 0.000 description 4
230000000644 propagated effect Effects 0.000 description 4
239000000376 reactant Substances 0.000 description 4
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
239000012279 sodium borohydride Substances 0.000 description 4
229910000033 sodium borohydride Inorganic materials 0.000 description 4
229960005322 streptomycin Drugs 0.000 description 4
125000004646 sulfenyl group Chemical group S(*)* 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 4
125000003396 thiol group Chemical class [H]S* 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
239000001226 triphosphate Substances 0.000 description 4
235000011178 triphosphate Nutrition 0.000 description 4
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 4
229960004441 tyrosine Drugs 0.000 description 4
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 3
DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 3
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
208000002077 Coxsackievirus Infections Diseases 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
241001492220 Echovirus E2 Species 0.000 description 3
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
108010047761 Interferon-alpha Proteins 0.000 description 3
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
229910017906 NH3H2O Inorganic materials 0.000 description 3
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 3
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 3
BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 3
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 3
125000001118 alkylidene group Chemical group 0.000 description 3
QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical group CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 3
HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 3
229940000635 beta-alanine Drugs 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
230000037396 body weight Effects 0.000 description 3
JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 3
239000003638 chemical reducing agent Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 3
229940125782 compound 2 Drugs 0.000 description 3
238000011262 co‐therapy Methods 0.000 description 3
125000004093 cyano group Chemical group *C#N 0.000 description 3
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
125000004185 ester group Chemical group 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000000605 extraction Methods 0.000 description 3
229960003692 gamma aminobutyric acid Drugs 0.000 description 3
230000036541 health Effects 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
150000001261 hydroxy acids Chemical group 0.000 description 3
238000002372 labelling Methods 0.000 description 3
238000005259 measurement Methods 0.000 description 3
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
150000003833 nucleoside derivatives Chemical class 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
229960003104 ornithine Drugs 0.000 description 3
IFPHDUVGLXEIOQ-UHFFFAOYSA-N ortho-iodosylbenzoic acid Chemical class OC(=O)C1=CC=CC=C1I=O IFPHDUVGLXEIOQ-UHFFFAOYSA-N 0.000 description 3
239000007800 oxidant agent Substances 0.000 description 3
229960003531 phenolsulfonphthalein Drugs 0.000 description 3
229910000027 potassium carbonate Inorganic materials 0.000 description 3
230000002265 prevention Effects 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
150000003217 pyrazoles Chemical class 0.000 description 3
229920002477 rna polymer Polymers 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
229910052710 silicon Inorganic materials 0.000 description 3
239000010703 silicon Substances 0.000 description 3
238000009097 single-agent therapy Methods 0.000 description 3
CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
238000007614 solvation Methods 0.000 description 3
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 3
239000000725 suspension Substances 0.000 description 3
GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
125000005039 triarylmethyl group Chemical group 0.000 description 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
229940035893 uracil Drugs 0.000 description 3
230000029812 viral genome replication Effects 0.000 description 3
239000005723 virus inoculator Substances 0.000 description 3
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 2
LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical group ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 2
WQADWIOXOXRPLN-UHFFFAOYSA-N 1,3-dithiane Chemical compound C1CSCSC1 WQADWIOXOXRPLN-UHFFFAOYSA-N 0.000 description 2
150000004865 1,3-dithiolanes Chemical class 0.000 description 2
JBWYRBLDOOOJEU-UHFFFAOYSA-N 1-[chloro-(4-methoxyphenyl)-phenylmethyl]-4-methoxybenzene Chemical compound C1=CC(OC)=CC=C1C(Cl)(C=1C=CC(OC)=CC=1)C1=CC=CC=C1 JBWYRBLDOOOJEU-UHFFFAOYSA-N 0.000 description 2
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 2
208000034579 Acute haemorrhagic conjunctivitis Diseases 0.000 description 2
HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
235000017060 Arachis glabrata Nutrition 0.000 description 2
241001553178 Arachis glabrata Species 0.000 description 2
235000010777 Arachis hypogaea Nutrition 0.000 description 2
235000018262 Arachis monticola Nutrition 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
239000004215 Carbon black (E152) Substances 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
241000709675 Coxsackievirus B3 Species 0.000 description 2
UQBOJOOOTLPNST-UHFFFAOYSA-N Dehydroalanine Chemical compound NC(=C)C(O)=O UQBOJOOOTLPNST-UHFFFAOYSA-N 0.000 description 2
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical class COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
208000005235 Echovirus Infections Diseases 0.000 description 2
206010014909 Enterovirus infection Diseases 0.000 description 2
206010014978 Epidemic pleurodynia Diseases 0.000 description 2
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
241000710198 Foot-and-mouth disease virus Species 0.000 description 2
241001529465 Human parechovirus 2 Species 0.000 description 2
102100040019 Interferon alpha-1/13 Human genes 0.000 description 2
102100040018 Interferon alpha-2 Human genes 0.000 description 2
108010005716 Interferon beta-1a Proteins 0.000 description 2
101710175886 Interferon gamma 1 Proteins 0.000 description 2
102000006992 Interferon-alpha Human genes 0.000 description 2
108010079944 Interferon-alpha2b Proteins 0.000 description 2
108010074328 Interferon-gamma Proteins 0.000 description 2
102000008070 Interferon-gamma Human genes 0.000 description 2
201000009906 Meningitis Diseases 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
241001122315 Polites Species 0.000 description 2
241000720974 Protium Species 0.000 description 2
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
206010037660 Pyrexia Diseases 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
GLYOPNLBKCBTMI-UHFFFAOYSA-N [2-chloro-2-(1-chloro-2-phenylethoxy)ethyl]benzene Chemical compound C=1C=CC=CC=1CC(Cl)OC(Cl)CC1=CC=CC=C1 GLYOPNLBKCBTMI-UHFFFAOYSA-N 0.000 description 2
CGTWCAVZZBLHQH-UHFFFAOYSA-N [cyano-(3-phenoxyphenyl)methyl] 2,2-dichloro-1-(4-ethoxyphenyl)cyclopropane-1-carboxylate Chemical compound C1=CC(OCC)=CC=C1C1(C(=O)OC(C#N)C=2C=C(OC=3C=CC=CC=3)C=CC=2)C(Cl)(Cl)C1 CGTWCAVZZBLHQH-UHFFFAOYSA-N 0.000 description 2
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
150000003973 alkyl amines Chemical class 0.000 description 2
125000004448 alkyl carbonyl group Chemical group 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000008485 antagonism Effects 0.000 description 2
230000000340 anti-metabolite Effects 0.000 description 2
229940100197 antimetabolite Drugs 0.000 description 2
239000002256 antimetabolite Substances 0.000 description 2
230000004596 appetite loss Effects 0.000 description 2
125000003710 aryl alkyl group Chemical group 0.000 description 2
CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 description 2
230000037058 blood plasma level Effects 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 2
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
125000002837 carbocyclic group Chemical group 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
229940126543 compound 14 Drugs 0.000 description 2
229940125807 compound 37 Drugs 0.000 description 2
230000002079 cooperative effect Effects 0.000 description 2
239000013078 crystal Substances 0.000 description 2
GCFAUZGWPDYAJN-UHFFFAOYSA-N cyclohexyl 3-phenylprop-2-enoate Chemical compound C=1C=CC=CC=1C=CC(=O)OC1CCCCC1 GCFAUZGWPDYAJN-UHFFFAOYSA-N 0.000 description 2
PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
230000000120 cytopathologic effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 2
239000001177 diphosphate Substances 0.000 description 2
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
235000011180 diphosphates Nutrition 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
239000003797 essential amino acid Substances 0.000 description 2
235000020776 essential amino acid Nutrition 0.000 description 2
CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
239000006260 foam Substances 0.000 description 2
238000005187 foaming Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
125000004446 heteroarylalkyl group Chemical group 0.000 description 2
229950007035 homocamfin Drugs 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
125000001967 indiganyl group Chemical group [H][In]([H])[*] 0.000 description 2
IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 2
DRAVOWXCEBXPTN-UHFFFAOYSA-N isoguanine Chemical compound NC1=NC(=O)NC2=C1NC=N2 DRAVOWXCEBXPTN-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 2
239000010410 layer Substances 0.000 description 2
QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 2
239000002502 liposome Substances 0.000 description 2
208000019423 liver disease Diseases 0.000 description 2
208000019017 loss of appetite Diseases 0.000 description 2
235000021266 loss of appetite Nutrition 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
229940098779 methanesulfonic acid Drugs 0.000 description 2
KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical class COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
230000000116 mitigating effect Effects 0.000 description 2
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
229910017604 nitric acid Inorganic materials 0.000 description 2
125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 2
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
125000004430 oxygen atom Chemical group O* 0.000 description 2
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
235000020232 peanut Nutrition 0.000 description 2
108010092851 peginterferon alfa-2b Proteins 0.000 description 2
229940106366 pegintron Drugs 0.000 description 2
230000006320 pegylation Effects 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 2
210000002381 plasma Anatomy 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
125000003367 polycyclic group Chemical group 0.000 description 2
KDESEECZHLTGMH-QMMMGPOBSA-N propan-2-yl (2s)-2-amino-4-methylpentanoate Chemical compound CC(C)C[C@H](N)C(=O)OC(C)C KDESEECZHLTGMH-QMMMGPOBSA-N 0.000 description 2
QDQVXVRZVCTVHE-YFKPBYRVSA-N propan-2-yl (2s)-2-aminopropanoate Chemical compound CC(C)OC(=O)[C@H](C)N QDQVXVRZVCTVHE-YFKPBYRVSA-N 0.000 description 2
OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical compound [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 description 2
NPRDHMWYZHSAHR-UHFFFAOYSA-N pyridine;trioxochromium Chemical compound O=[Cr](=O)=O.C1=CC=NC=C1.C1=CC=NC=C1 NPRDHMWYZHSAHR-UHFFFAOYSA-N 0.000 description 2
150000003233 pyrroles Chemical class 0.000 description 2
XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
238000011160 research Methods 0.000 description 2
229960000329 ribavirin Drugs 0.000 description 2
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 2
CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 2
229960004889 salicylic acid Drugs 0.000 description 2
125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
239000012453 solvate Substances 0.000 description 2
KXCAEQNNTZANTK-UHFFFAOYSA-N stannane Chemical compound [SnH4] KXCAEQNNTZANTK-UHFFFAOYSA-N 0.000 description 2
229910000080 stannane Inorganic materials 0.000 description 2
125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 2
ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
229940095068 tetradecene Drugs 0.000 description 2
YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
125000005031 thiocyano group Chemical group S(C#N)* 0.000 description 2
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
229910052722 tritium Inorganic materials 0.000 description 2
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
229920002554 vinyl polymer Polymers 0.000 description 2
229940075420 xanthine Drugs 0.000 description 2
ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
RNEACARJKXYVND-KQGZCTBQSA-N (2r)-2-[[(5z)-5-[(5-ethylfuran-2-yl)methylidene]-4-oxo-1,3-thiazol-2-yl]amino]-2-(4-fluorophenyl)acetic acid Chemical compound O1C(CC)=CC=C1\C=C/1C(=O)N=C(N[C@@H](C(O)=O)C=2C=CC(F)=CC=2)S\1 RNEACARJKXYVND-KQGZCTBQSA-N 0.000 description 1
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
WTHNBLKUMCPUFE-UHFFFAOYSA-N (4-oxo-1,3,2,4lambda5-dioxathiaphosphetan-4-yl) phosphono hydrogen phosphate Chemical class OP(=O)(O)OP(=O)(O)OP1(=O)OSO1 WTHNBLKUMCPUFE-UHFFFAOYSA-N 0.000 description 1
YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 description 1
PMJHHCWVYXUKFD-SNAWJCMRSA-N (E)-1,3-pentadiene Chemical compound C\C=C\C=C PMJHHCWVYXUKFD-SNAWJCMRSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
150000005070 1,2,3-oxadiazoles Chemical class 0.000 description 1
UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical class C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 1
JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
150000005071 1,2,4-oxadiazoles Chemical class 0.000 description 1
YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical class C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 1
KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
VUMCUSHVMYIRMB-UHFFFAOYSA-N 1,3,5-tri(propan-2-yl)benzene Chemical class CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1 VUMCUSHVMYIRMB-UHFFFAOYSA-N 0.000 description 1
LKLLNYWECKEQIB-UHFFFAOYSA-N 1,3,5-triazinane Chemical class C1NCNCN1 LKLLNYWECKEQIB-UHFFFAOYSA-N 0.000 description 1
BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical compound C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 description 1
VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
150000000093 1,3-dioxanes Chemical class 0.000 description 1
QVFHFKPGBODJJB-UHFFFAOYSA-N 1,3-oxathiane Chemical compound C1COCSC1 QVFHFKPGBODJJB-UHFFFAOYSA-N 0.000 description 1
WJJSZTJGFCFNKI-UHFFFAOYSA-N 1,3-oxathiolane Chemical class C1CSCO1 WJJSZTJGFCFNKI-UHFFFAOYSA-N 0.000 description 1
OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
150000000094 1,4-dioxanes Chemical class 0.000 description 1
JBYHSSAVUBIJMK-UHFFFAOYSA-N 1,4-oxathiane Chemical compound C1CSCCO1 JBYHSSAVUBIJMK-UHFFFAOYSA-N 0.000 description 1
OBOHMJWDFPBPKD-UHFFFAOYSA-N 1-[chloro(diphenyl)methyl]-4-methoxybenzene Chemical compound C1=CC(OC)=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 OBOHMJWDFPBPKD-UHFFFAOYSA-N 0.000 description 1
UZASMYQTKALYAA-UHFFFAOYSA-N 1-benzothiophene 1H-pyrrole Chemical class N1C=CC=C1.S1C=CC2=C1C=CC=C2 UZASMYQTKALYAA-UHFFFAOYSA-N 0.000 description 1
MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical class CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
CUCJJMLDIUSNPU-UHFFFAOYSA-N 1-oxidopiperidin-1-ium Chemical compound [O-][NH+]1CCCCC1 CUCJJMLDIUSNPU-UHFFFAOYSA-N 0.000 description 1
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
YTQQIHUQLOZOJI-UHFFFAOYSA-N 2,3-dihydro-1,2-thiazole Chemical compound C1NSC=C1 YTQQIHUQLOZOJI-UHFFFAOYSA-N 0.000 description 1
GVZJRBAUSGYWJI-UHFFFAOYSA-N 2,5-bis(3-dodecylthiophen-2-yl)thiophene Chemical compound C1=CSC(C=2SC(=CC=2)C2=C(C=CS2)CCCCCCCCCCCC)=C1CCCCCCCCCCCC GVZJRBAUSGYWJI-UHFFFAOYSA-N 0.000 description 1
JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 description 1
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
125000001431 2-aminoisobutyric acid group Chemical class [#6]C([#6])(N*)C(*)=O 0.000 description 1
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
ZRNSSRODJSSVEJ-UHFFFAOYSA-N 2-methylpentacosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(C)C ZRNSSRODJSSVEJ-UHFFFAOYSA-N 0.000 description 1
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
WDGCBNTXZHJTHJ-UHFFFAOYSA-N 2h-1,3-oxazol-2-id-4-one Chemical class O=C1CO[C-]=N1 WDGCBNTXZHJTHJ-UHFFFAOYSA-N 0.000 description 1
BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical class N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
VAJVDSVGBWFCLW-UHFFFAOYSA-N 3-Phenyl-1-propanol Chemical compound OCCCC1=CC=CC=C1 VAJVDSVGBWFCLW-UHFFFAOYSA-N 0.000 description 1
BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 1
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical class O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 1
NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
VKKXEIQIGGPMHT-UHFFFAOYSA-N 7h-purine-2,8-diamine Chemical compound NC1=NC=C2NC(N)=NC2=N1 VKKXEIQIGGPMHT-UHFFFAOYSA-N 0.000 description 1
ARAZHTGXOXPAFK-UHFFFAOYSA-N 9-phenylxanthene Chemical compound C12=CC=CC=C2OC2=CC=CC=C2[C]1C1=CC=CC=C1 ARAZHTGXOXPAFK-UHFFFAOYSA-N 0.000 description 1
206010000087 Abdominal pain upper Diseases 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
241000710189 Aphthovirus Species 0.000 description 1
241001651353 Avihepatovirus Species 0.000 description 1
108091032955 Bacterial small RNA Proteins 0.000 description 1
239000004342 Benzoyl peroxide Substances 0.000 description 1
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
241000131971 Bradyrhizobiaceae Species 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
DGFQXXDHYHWWSP-UHFFFAOYSA-N CC(C)OC([O])=O Chemical compound CC(C)OC([O])=O DGFQXXDHYHWWSP-UHFFFAOYSA-N 0.000 description 1
JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 1
229940127007 Compound 39 Drugs 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
238000005675 Corey-Kim oxidation reaction Methods 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
241000146316 Coxsackievirus A20 Species 0.000 description 1
102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
206010013710 Drug interaction Diseases 0.000 description 1
241001492221 Echovirus E12 Species 0.000 description 1
241000217423 Echovirus E19 Species 0.000 description 1
241000217450 Echovirus E29 Species 0.000 description 1
241001468007 Erbovirus Species 0.000 description 1
108090000371 Esterases Proteins 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229910004373 HOAc Inorganic materials 0.000 description 1
208000020061 Hand, Foot and Mouth Disease Diseases 0.000 description 1
208000025713 Hand-foot-and-mouth disease Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
201000006219 Herpangina Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 1
101001002469 Homo sapiens Interferon lambda-2 Proteins 0.000 description 1
241000709716 Human enterovirus 70 Species 0.000 description 1
241000709694 Human parechovirus 1 Species 0.000 description 1
WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
108010078049 Interferon alpha-2 Proteins 0.000 description 1
102100020990 Interferon lambda-1 Human genes 0.000 description 1
101710099623 Interferon lambda-1 Proteins 0.000 description 1
102100020989 Interferon lambda-2 Human genes 0.000 description 1
102100020992 Interferon lambda-3 Human genes 0.000 description 1
101710099621 Interferon lambda-3 Proteins 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
206010023126 Jaundice Diseases 0.000 description 1
241001468006 Kobuvirus Species 0.000 description 1
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
241000270322 Lepidosauria Species 0.000 description 1
229910010084 LiAlH4 Inorganic materials 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
101100189356 Mus musculus Papolb gene Proteins 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
208000009525 Myocarditis Diseases 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
229910003827 NRaRb Inorganic materials 0.000 description 1
206010028735 Nasal congestion Diseases 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
229910021585 Nickel(II) bromide Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
JWIPGAFCGUDKEY-UHFFFAOYSA-L O[Cr](Cl)(=O)=O.C1=CC=NC=C1 Chemical compound O[Cr](Cl)(=O)=O.C1=CC=NC=C1 JWIPGAFCGUDKEY-UHFFFAOYSA-L 0.000 description 1
206010068319 Oropharyngeal pain Diseases 0.000 description 1
WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
229910019213 POCl3 Inorganic materials 0.000 description 1
241000282577 Pan troglodytes Species 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
208000033952 Paralysis flaccid Diseases 0.000 description 1
241000991583 Parechovirus Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
241000009328 Perro Species 0.000 description 1
201000007100 Pharyngitis Diseases 0.000 description 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropyl alcohol Natural products CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 1
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
241000288906 Primates Species 0.000 description 1
239000004365 Protease Substances 0.000 description 1
230000006819 RNA synthesis Effects 0.000 description 1
102000018120 Recombinases Human genes 0.000 description 1
108010091086 Recombinases Proteins 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
206010061494 Rhinovirus infection Diseases 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
241001352312 Salivirus Species 0.000 description 1
241001333897 Sapelovirus Species 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
241001632234 Senecavirus Species 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
238000003800 Staudinger reaction Methods 0.000 description 1
238000006859 Swern oxidation reaction Methods 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
241000249096 Teschovirus Species 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
241001365589 Tremovirus Species 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
AXNBHOOQHIIQFA-UHFFFAOYSA-N [S].C(F)(F)F Chemical compound [S].C(F)(F)F AXNBHOOQHIIQFA-UHFFFAOYSA-N 0.000 description 1
206010000059 abdominal discomfort Diseases 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
125000002015 acyclic group Chemical group 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
108010080374 albuferon Proteins 0.000 description 1
125000003158 alcohol group Chemical group 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
150000001345 alkine derivatives Chemical class 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
XYLMUPLGERFSHI-UHFFFAOYSA-N alpha-Methylstyrene Chemical compound CC(=C)C1=CC=CC=C1 XYLMUPLGERFSHI-UHFFFAOYSA-N 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
239000004855 amber Substances 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
NEHMKBQYUWJMIP-UHFFFAOYSA-N anhydrous methyl chloride Natural products ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
125000005002 aryl methyl group Chemical group 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
XEMXAGJRXIFZOQ-UHFFFAOYSA-N azanium;2,2-diethylbutanoate Chemical compound [NH4+].CCC(CC)(CC)C([O-])=O XEMXAGJRXIFZOQ-UHFFFAOYSA-N 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
230000006399 behavior Effects 0.000 description 1
125000005605 benzo group Chemical group 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
235000019400 benzoyl peroxide Nutrition 0.000 description 1
125000001743 benzylic group Chemical group 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
150000001576 beta-amino acids Chemical class 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
208000025698 brain inflammatory disease Diseases 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
235000014121 butter Nutrition 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
ZPFKRQXYKULZKP-UHFFFAOYSA-N butylidene Chemical group [CH2+]CC[CH-] ZPFKRQXYKULZKP-UHFFFAOYSA-N 0.000 description 1
229960001948 caffeine Drugs 0.000 description 1
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
210000000234 capsid Anatomy 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
238000012054 celltiter-glo Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229910052729 chemical element Inorganic materials 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
125000000259 cinnolinyl group Chemical class N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
229960004106 citric acid Drugs 0.000 description 1
238000005253 cladding Methods 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
229940125797 compound 12 Drugs 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
229940127573 compound 38 Drugs 0.000 description 1
229940125936 compound 42 Drugs 0.000 description 1
229940125844 compound 46 Drugs 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
229940124301 concurrent medication Drugs 0.000 description 1
238000006482 condensation reaction Methods 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000002920 convulsive effect Effects 0.000 description 1
OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
QFKWSRIUZIYLCK-UHFFFAOYSA-J copper;disodium;hydrogen carbonate;2-hydroxypropane-1,2,3-tricarboxylic acid;hydroxide;sulfate Chemical compound [OH-].[Na+].[Na+].[Cu+2].OC([O-])=O.[O-]S([O-])(=O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O QFKWSRIUZIYLCK-UHFFFAOYSA-J 0.000 description 1
238000005336 cracking Methods 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
FQQOMPOPYZIROF-UHFFFAOYSA-N cyclopenta-2,4-dien-1-one Chemical group O=C1C=CC=C1 FQQOMPOPYZIROF-UHFFFAOYSA-N 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
238000006356 dehydrogenation reaction Methods 0.000 description 1
108010086003 delta interferon Proteins 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000010612 desalination reaction Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 1
125000005265 dialkylamine group Chemical group 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
LRHDNAVPELLXDL-UHFFFAOYSA-N difluoromethylsulfonylbenzene Chemical compound FC(F)S(=O)(=O)C1=CC=CC=C1 LRHDNAVPELLXDL-UHFFFAOYSA-N 0.000 description 1
125000004982 dihaloalkyl group Chemical group 0.000 description 1
NKRNGKIEDAVMHL-UHFFFAOYSA-L dihydroxy(dioxo)chromium;pyridine Chemical compound O[Cr](O)(=O)=O.C1=CC=NC=C1 NKRNGKIEDAVMHL-UHFFFAOYSA-L 0.000 description 1
229940043279 diisopropylamine Drugs 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
BXNKCKFDLBMOTA-UHFFFAOYSA-N dioxol-3-one Chemical compound O=C1C=COO1 BXNKCKFDLBMOTA-UHFFFAOYSA-N 0.000 description 1
SNQXJPARXFUULZ-UHFFFAOYSA-N dioxolane Chemical compound C1COOC1 SNQXJPARXFUULZ-UHFFFAOYSA-N 0.000 description 1
ROORDVPLFPIABK-UHFFFAOYSA-N diphenyl carbonate Chemical compound C=1C=CC=CC=1OC(=O)OC1=CC=CC=C1 ROORDVPLFPIABK-UHFFFAOYSA-N 0.000 description 1
XQRLCLUYWUNEEH-UHFFFAOYSA-N diphosphonic acid Chemical compound OP(=O)OP(O)=O XQRLCLUYWUNEEH-UHFFFAOYSA-N 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
150000002085 enols Chemical group 0.000 description 1
125000004050 enoyl group Chemical group 0.000 description 1
150000002118 epoxides Chemical class 0.000 description 1
MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 1
229940035423 ethyl ether Drugs 0.000 description 1
125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000004744 fabric Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
208000028331 flaccid paralysis Diseases 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
239000011888 foil Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
150000002240 furans Chemical class 0.000 description 1
JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
230000004927 fusion Effects 0.000 description 1
229940044627 gamma-interferon Drugs 0.000 description 1
239000000499 gel Substances 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
239000003292 glue Substances 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
238000000227 grinding Methods 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000035876 healing Effects 0.000 description 1
150000002373 hemiacetals Chemical class 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
230000020245 homoiothermy Effects 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
150000001469 hydantoins Chemical class 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
150000003949 imides Chemical class 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
150000002473 indoazoles Chemical class 0.000 description 1
150000002475 indoles Chemical class 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
229940090438 infergen Drugs 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000003993 interaction Effects 0.000 description 1
108010010648 interferon alfacon-1 Proteins 0.000 description 1
229960004461 interferon beta-1a Drugs 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
108700027921 interferon tau Proteins 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
GRHBQAYDJPGGLF-UHFFFAOYSA-N isothiocyanic acid Chemical compound N=C=S GRHBQAYDJPGGLF-UHFFFAOYSA-N 0.000 description 1
150000002545 isoxazoles Chemical class 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
150000003951 lactams Chemical class 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229960000448 lactic acid Drugs 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229910001623 magnesium bromide Inorganic materials 0.000 description 1
TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229940099690 malic acid Drugs 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
FYFFGSSZFBZTAH-UHFFFAOYSA-N methylaminomethanetriol Chemical compound CNC(O)(O)O FYFFGSSZFBZTAH-UHFFFAOYSA-N 0.000 description 1
PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
NBVXSUQYWXRMNV-UHFFFAOYSA-N monofluoromethane Natural products FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
239000000178 monomer Substances 0.000 description 1
150000004712 monophosphates Chemical class 0.000 description 1
230000036473 myasthenia Effects 0.000 description 1
DSWNRHCOGVRDOE-UHFFFAOYSA-N n,n-dimethylmethanimidamide Chemical compound CN(C)C=N DSWNRHCOGVRDOE-UHFFFAOYSA-N 0.000 description 1
MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
LWFWUJCJKPUZLV-UHFFFAOYSA-N n-trimethylsilylacetamide Chemical class CC(=O)N[Si](C)(C)C LWFWUJCJKPUZLV-UHFFFAOYSA-N 0.000 description 1
PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
229940127073 nucleoside analogue Drugs 0.000 description 1
235000014571 nuts Nutrition 0.000 description 1
PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
230000004768 organ dysfunction Effects 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
125000002524 organometallic group Chemical group 0.000 description 1
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
150000002905 orthoesters Chemical class 0.000 description 1
HXNFUBHNUDHIGC-UHFFFAOYSA-N oxypurinol Chemical compound O=C1NC(=O)N=C2NNC=C21 HXNFUBHNUDHIGC-UHFFFAOYSA-N 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
208000035824 paresthesia Diseases 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229940002988 pegasys Drugs 0.000 description 1
108010092853 peginterferon alfa-2a Proteins 0.000 description 1
230000035515 penetration Effects 0.000 description 1
208000008494 pericarditis Diseases 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
PMOIAJVKYNVHQE-UHFFFAOYSA-N phosphanium;bromide Chemical compound [PH4+].[Br-] PMOIAJVKYNVHQE-UHFFFAOYSA-N 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
125000004437 phosphorous atom Chemical group 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical class C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
JTHRRMFZHSDGNJ-UHFFFAOYSA-N piperazine-2,3-dione Chemical compound O=C1NCCNC1=O JTHRRMFZHSDGNJ-UHFFFAOYSA-N 0.000 description 1
150000003053 piperidines Chemical class 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
230000004224 protection Effects 0.000 description 1
CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical class O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
QFYXSLAAXZTRLG-UHFFFAOYSA-N pyrrolidine-2,3-dione Chemical class O=C1CCNC1=O QFYXSLAAXZTRLG-UHFFFAOYSA-N 0.000 description 1
150000003235 pyrrolidines Chemical class 0.000 description 1
150000004040 pyrrolidinones Chemical class 0.000 description 1
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
229940038850 rebif Drugs 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
125000006413 ring segment Chemical group 0.000 description 1
229910052701 rubidium Inorganic materials 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000035807 sensation Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
235000015170 shellfish Nutrition 0.000 description 1
229910000077 silane Inorganic materials 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
235000017550 sodium carbonate Nutrition 0.000 description 1
KIEOKOFEPABQKJ-UHFFFAOYSA-N sodium dichromate Chemical compound [Na+].[Na+].[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O KIEOKOFEPABQKJ-UHFFFAOYSA-N 0.000 description 1
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
241000894007 species Species 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
230000003319 supportive effect Effects 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229960001367 tartaric acid Drugs 0.000 description 1
238000003419 tautomerization reaction Methods 0.000 description 1
MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000012360 testing method Methods 0.000 description 1
DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
229960004559 theobromine Drugs 0.000 description 1
150000004867 thiadiazoles Chemical class 0.000 description 1
CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
125000005270 trialkylamine group Chemical group 0.000 description 1
150000003852 triazoles Chemical class 0.000 description 1
FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
GRGCWBWNLSTIEN-UHFFFAOYSA-N trifluoromethanesulfonyl chloride Chemical compound FC(F)(F)S(Cl)(=O)=O GRGCWBWNLSTIEN-UHFFFAOYSA-N 0.000 description 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
125000004385 trihaloalkyl group Chemical group 0.000 description 1
PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
229940094989 trimethylsilane Drugs 0.000 description 1
FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
BPLKQGGAXWRFOE-UHFFFAOYSA-M trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 1
150000004901 trioxanes Chemical class 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229940116269 uric acid Drugs 0.000 description 1
230000008673 vomiting Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Oncology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

CN201580076647.5A 2014-12-19 2015-12-16 被取代的核苷、核苷酸及其类似物 Pending CN107250145A (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462094418P	2014-12-19	2014-12-19
US62/094418		2014-12-19
PCT/US2015/066193 WO2016100569A1 (en)	2014-12-19	2015-12-16	Substituted nucleosides, nucleotides and analogs thereof

Publications (1)

Publication Number	Publication Date
CN107250145A true CN107250145A (zh)	2017-10-13

Family

ID=56127561

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN201580076647.5A Pending CN107250145A (zh)	2014-12-19	2015-12-16	被取代的核苷、核苷酸及其类似物

Country Status (12)

Country	Link
US (2)	US9890188B2 (2)
EP (1)	EP3233879A4 (2)
JP (1)	JP2017538722A (2)
CN (1)	CN107250145A (2)
AU (1)	AU2015364630A1 (2)
CA (1)	CA2970936A1 (2)
HK (1)	HK1245800A1 (2)
MA (1)	MA41213A (2)
MX (1)	MX2017008184A (2)
TW (1)	TW201625658A (2)
WO (1)	WO2016100569A1 (2)
ZA (1)	ZA201704876B (2)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN114288313A (zh) *	2022-02-18	2022-04-08	常晓宇	嘧啶核苷类药物在制备预防或治疗冠状病毒感染性疾病药物中的用途
WO2023142803A1 (zh) *	2022-01-28	2023-08-03	北京恩泰伟医药科技有限公司	抗病毒化合物及其用途

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG10201913554YA (en)	2011-12-22	2020-03-30	Alios Biopharma Inc	Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en)	2012-03-21	2020-08-25	Janssen Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
HK1206362A1 (zh)	2012-03-21	2016-01-08	Alios Biopharma, Inc.	硫代氨基磷酸酯核苷酸前藥的固體形式
US9441007B2 (en)	2012-03-21	2016-09-13	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
BR112015014457A2 (pt)	2012-12-21	2017-11-21	Alios Biopharma Inc	composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
US9598457B2 (en)	2012-12-21	2017-03-21	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
CA2908313A1 (en)	2013-04-05	2014-10-09	Alios Biopharma, Inc.	Hepatitis c viral infection treatment using a combination of compounds
MX2015017556A (es)	2013-06-26	2016-05-09	Alios Biopharma Inc	Nucleosidos sustituidos, nucleotidos y analogos de los mismos.
AU2014302711A1 (en)	2013-06-26	2015-12-10	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
WO2015054465A1 (en)	2013-10-11	2015-04-16	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
HUE051986T2 (hu)	2014-06-24	2021-04-28	Janssen Biopharma Inc	Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra
MA40031A (fr)	2014-06-24	2015-12-30	Alios Biopharma Inc	Nucléosides substitués, nucléotides et analogues de ceux-ci
WO2016069489A1 (en)	2014-10-28	2016-05-06	Alios Biopharma, Inc.	Methods of preparing substituted nucleoside analogs
MA41441A (fr)	2014-12-19	2017-12-12	Alios Biopharma Inc	Nucléosides substitués, nucléotides et analogues de ceux-ci
CA3182565A1 (en)	2015-03-06	2016-09-15	Atea Pharmaceuticals, Inc.	.beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
US10208045B2 (en)	2015-03-11	2019-02-19	Alios Biopharma, Inc.	Aza-pyridone compounds and uses thereof
TW201718618A (zh) *	2015-09-18	2017-06-01	田邊三菱製藥股份有限公司	架橋型核酸ＧｕＮＡ，其製造方法，及中間體化合物
US10202412B2 (en)	2016-07-08	2019-02-12	Atea Pharmaceuticals, Inc.	β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018048937A1 (en)	2016-09-07	2018-03-15	Atea Pharmaceuticals, Inc.	2'-substituted-n6-substituted purine nucleotides for rna virus treatment
WO2018110591A1 (ja) *	2016-12-13	2018-06-21	ヤマサ醤油株式会社	抗ウイルス活性を有する２'－デオキシ－７－デアザプリンヌクレオシド誘導体
IL288737B (en)	2017-02-01	2022-09-01	Atea Pharmaceuticals Inc	Hemisulfate nucleotide salt for treatment of hepatitis c virus
CA3075950A1 (en) *	2017-09-18	2019-03-21	Janssen Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
EP3773753A4 (en)	2018-04-10	2021-12-22	ATEA Pharmaceuticals, Inc.	TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
CN113811360A (zh)	2019-03-06	2021-12-17	葛兰素史密斯克莱知识产权（第2 号）有限公司	用于hiv治疗的化合物
KR20250133471A (ko)	2020-02-18	2025-09-05	길리애드 사이언시즈, 인코포레이티드	항바이러스 화합물
TWI883391B (zh)	2020-02-18	2025-05-11	美商基利科學股份有限公司	抗病毒化合物
TWI775313B (zh)	2020-02-18	2022-08-21	美商基利科學股份有限公司	抗病毒化合物
US10874687B1 (en)	2020-02-27	2020-12-29	Atea Pharmaceuticals, Inc.	Highly active compounds against COVID-19
WO2021188959A1 (en)	2020-03-20	2021-09-23	Gilead Sciences, Inc.	Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
US12274700B1 (en)	2020-10-30	2025-04-15	Accencio LLC	Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
CA3216162A1 (en)	2021-04-16	2022-10-20	Gilead Sciences, Inc.	Methods of preparing carbanucleosides using amides
IL308921A (en)	2021-06-17	2024-01-01	Atea Pharmaceuticals Inc	Combination anti-HCV therapy is beneficial
AU2022328698B2 (en)	2021-08-18	2025-02-20	Gilead Sciences, Inc.	Phospholipid compounds and methods of making and using the same
US20250032527A1 (en)	2021-11-01	2025-01-30	Immunic Ag	Medical use of n4-hydroxy citicoline compounds
IL315480A (en)	2022-03-15	2024-11-01	Rome Therapeutics Inc	Compounds and methods for treating disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005020884A2 (en) *	2003-05-14	2005-03-10	Idenix (Cayman) Limited	Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
EP1589026A1 (en) *	2004-03-24	2005-10-26	Yamasa Corporation	4'-C-Substituted-2-Haloadenosine derivative
CN105829333A (zh) *	2013-10-11	2016-08-03	艾丽奥斯生物制药有限公司	取代的核苷、核苷酸及其类似物
CN105979951A (zh) *	2014-02-06	2016-09-28	里博科学有限责任公司	作为流感rna复制的抑制剂的4’-二氟甲基取代的核苷衍生物
CN106795199A (zh) *	2014-03-28	2017-05-31	默沙东公司	作为hiv逆转录酶抑制剂的4’‑取代的核苷衍生物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5432272A (en)	1990-10-09	1995-07-11	Benner; Steven A.	Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
ATE250622T1 (de)	1999-05-12	2003-10-15	Yamasa Corp	4'-c-ethynyl-pyrimidine nukleoside
SK286630B6 (sk)	2001-01-22	2009-02-05	Merck & Co., Inc.	Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
GB0114286D0 (en)	2001-06-12	2001-08-01	Hoffmann La Roche	Nucleoside Derivatives
CN100532388C (zh) *	2007-07-16	2009-08-26	郑州大学	2’-氟-4’-取代-核苷类似物、其制备方法及应用
EP2207554A2 (en) *	2007-11-09	2010-07-21	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	C4'-substituted-2-deoxyadenosine analogs and methods of treating hiv
US20090318380A1 (en) *	2007-11-20	2009-12-24	Pharmasset, Inc.	2',4'-substituted nucleosides as antiviral agents
US8163707B2 (en) *	2008-09-15	2012-04-24	Enanta Pharmaceuticals, Inc.	4′-allene-substituted nucleoside derivatives
JP2012521359A (ja)	2009-03-20	2012-09-13	アリオスバイオファーマインク．	置換されたヌクレオシドアナログおよびヌクレオチドアナログ
BRPI1010809A2 (pt)	2009-05-12	2015-10-13	Southern Res Inst	composto, composição farmacêutica, métodos de tratar câncer em mamífero e usos de compostos e de composição farmacêutica
EP2619215B1 (en)	2010-09-22	2018-09-05	Alios Biopharma, Inc.	Azido nucleosides and nucleotide analogs
WO2012040126A1 (en)	2010-09-22	2012-03-29	Alios Biopharma, Inc.	Substituted nucleotide analogs
NZ607996A (en)	2010-09-22	2014-07-25	Alios Biopharma Inc	Substituted nucleotide analogs
CA2819041A1 (en)	2010-12-22	2012-06-28	Alios Biopharma, Inc.	Cyclic nucleotide analogs
CA2860234A1 (en)	2011-12-22	2013-06-27	Alios Biopharma, Inc.	Substituted phosphorothioate nucleotide analogs
SG10201913554YA (en)	2011-12-22	2020-03-30	Alios Biopharma Inc	Substituted nucleosides, nucleotides and analogs thereof
WO2013142159A1 (en)	2012-03-21	2013-09-26	Alios Biopharma, Inc.	Pharmaceutical combinations comprising a thionucleotide analog
US8846896B2 (en)	2012-03-21	2014-09-30	Alios Biopharma, Inc.	Methods of preparing substituted nucleotide analogs
US9441007B2 (en)	2012-03-21	2016-09-13	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
GEP201706721B (en)	2012-03-21	2017-08-25	Alios Biopharma Inc	Substituted nucleosides, nucleotides and analogs thereof
HK1206362A1 (zh)	2012-03-21	2016-01-08	Alios Biopharma, Inc.	硫代氨基磷酸酯核苷酸前藥的固體形式
WO2013142157A1 (en)	2012-03-22	2013-09-26	Alios Biopharma, Inc.	Pharmaceutical combinations comprising a thionucleotide analog
US9598457B2 (en)	2012-12-21	2017-03-21	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
BR112015014457A2 (pt)	2012-12-21	2017-11-21	Alios Biopharma Inc	composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
WO2014134251A1 (en)	2013-02-28	2014-09-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions
WO2014164533A1 (en)	2013-03-11	2014-10-09	Vertex Pharmaceuticals Incorporated	Methods of stereoselective synthesis of substituted nucleoside analogs
CA2908313A1 (en)	2013-04-05	2014-10-09	Alios Biopharma, Inc.	Hepatitis c viral infection treatment using a combination of compounds
MX2015017556A (es)	2013-06-26	2016-05-09	Alios Biopharma Inc	Nucleosidos sustituidos, nucleotidos y analogos de los mismos.
AU2014302711A1 (en)	2013-06-26	2015-12-10	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
AU2015280245A1 (en)	2014-06-24	2017-01-05	Alios Biopharma, Inc.	Methods of preparing substituted nucleotide analogs
MA40031A (fr)	2014-06-24	2015-12-30	Alios Biopharma Inc	Nucléosides substitués, nucléotides et analogues de ceux-ci
HUE051986T2 (hu)	2014-06-24	2021-04-28	Janssen Biopharma Inc	Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra
CA2955604A1 (en)	2014-07-22	2016-01-28	Alios Biopharma, Inc.	Methods for treating paramyxoviruses
PE20170673A1 (es)	2014-08-05	2017-05-22	Alios Biopharma Inc	Terapia de combinacion para tratar una paramixovirus
WO2016069489A1 (en)	2014-10-28	2016-05-06	Alios Biopharma, Inc.	Methods of preparing substituted nucleoside analogs
MA41441A (fr)	2014-12-19	2017-12-12	Alios Biopharma Inc	Nucléosides substitués, nucléotides et analogues de ceux-ci

2015
- 2015-12-15 MA MA041213A patent/MA41213A/fr unknown
- 2015-12-16 US US14/971,926 patent/US9890188B2/en not_active Expired - Fee Related
- 2015-12-16 HK HK18105072.0A patent/HK1245800A1/zh unknown
- 2015-12-16 CA CA2970936A patent/CA2970936A1/en not_active Abandoned
- 2015-12-16 WO PCT/US2015/066193 patent/WO2016100569A1/en not_active Ceased
- 2015-12-16 MX MX2017008184A patent/MX2017008184A/es unknown
- 2015-12-16 CN CN201580076647.5A patent/CN107250145A/zh active Pending
- 2015-12-16 JP JP2017532656A patent/JP2017538722A/ja not_active Withdrawn
- 2015-12-16 EP EP15871022.8A patent/EP3233879A4/en not_active Withdrawn
- 2015-12-16 AU AU2015364630A patent/AU2015364630A1/en not_active Abandoned
- 2015-12-18 TW TW104142822A patent/TW201625658A/zh unknown
2017
- 2017-07-18 ZA ZA2017/04876A patent/ZA201704876B/en unknown
2018
- 2018-01-30 US US15/884,052 patent/US20180155384A1/en not_active Abandoned

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005020884A2 (en) *	2003-05-14	2005-03-10	Idenix (Cayman) Limited	Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
EP1589026A1 (en) *	2004-03-24	2005-10-26	Yamasa Corporation	4'-C-Substituted-2-Haloadenosine derivative
CN105829333A (zh) *	2013-10-11	2016-08-03	艾丽奥斯生物制药有限公司	取代的核苷、核苷酸及其类似物
CN105979951A (zh) *	2014-02-06	2016-09-28	里博科学有限责任公司	作为流感rna复制的抑制剂的4’-二氟甲基取代的核苷衍生物
CN106795199A (zh) *	2014-03-28	2017-05-31	默沙东公司	作为hiv逆转录酶抑制剂的4’‑取代的核苷衍生物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HIROTOMO NAKATA，等: "Activity against Human Immunodeficiency Virus Type 1, Intracellular Metabolism, and Effects on Human DNA Polymerases of 4"-Ethynyl-2-Fluoro-2"-Deoxyadenosine", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》 *
KENJI KITANO等: "Synthesis of 4"-C-Fluoromethylnucleosides as Potential Antineoplastic Agents", 《TETRAHEDRON》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2023142803A1 (zh) *	2022-01-28	2023-08-03	北京恩泰伟医药科技有限公司	抗病毒化合物及其用途
CN114288313A (zh) *	2022-02-18	2022-04-08	常晓宇	嘧啶核苷类药物在制备预防或治疗冠状病毒感染性疾病药物中的用途

Also Published As

Publication number	Publication date
MA41213A (fr)	2017-10-24
US20160176910A1 (en)	2016-06-23
AU2015364630A1 (en)	2017-07-06
US9890188B2 (en)	2018-02-13
HK1245800A1 (zh)	2018-08-31
TW201625658A (zh)	2016-07-16
US20180155384A1 (en)	2018-06-07
EP3233879A4 (en)	2018-09-19
WO2016100569A1 (en)	2016-06-23
JP2017538722A (ja)	2017-12-28
MX2017008184A (es)	2018-03-06
ZA201704876B (en)	2020-01-29
CA2970936A1 (en)	2016-06-23
EP3233879A1 (en)	2017-10-25

Legal Events

Date	Code	Title	Description
2017-10-13	PB01	Publication
2017-10-13	PB01	Publication
2018-01-19	SE01	Entry into force of request for substantive examination
2018-01-19	SE01	Entry into force of request for substantive examination
2020-09-22	WD01	Invention patent application deemed withdrawn after publication	Application publication date: 20171013
2020-09-22	WD01	Invention patent application deemed withdrawn after publication

Publication	Publication Date	Title
CN107250145A (zh)	2017-10-13	被取代的核苷、核苷酸及其类似物
Chandra et al.	2023	Fluorine-a small magic bullet atom in the drug development: perspective to FDA approved and COVID-19 recommended drugs
CN109890831A (zh)	2019-06-14	被取代的核苷、核苷酸以及它们的类似物
CN105408341B (zh)	2019-06-21	取代的核苷、核苷酸及其类似物
CA2952966C (en)	2024-10-29	SUBSTITUTE NUCLEOSIDES, NUCLEOTIDES AND THEIR ANALOGUES
CN106957282B (zh)	2019-08-30	B型肝炎抗病毒剂
JP2020534361A (ja)	2020-11-26	置換ヌクレオシド、ヌクレオチド、及びそのアナログ
CN109071467A (zh)	2018-12-21	无环抗病毒药
CN107459544A (zh)	2017-12-12	取代的核苷、核苷酸及其类似物
WO2013189237A1 (zh)	2013-12-27	穿心莲内酯类似物及其治疗的应用
TW201524990A (zh)	2015-07-01	經取代之核苷、核苷酸及其類似物
WO2002018404A9 (en)	2003-10-02	Nucleoside derivatives for the treatment of hepatitis c
CN102428093A (zh)	2012-04-25	基于吉西他滨结构的前药及其合成方法及应用
TW201538517A (zh)	2015-10-16	作為流感病毒ｒｎａ複製之抑制劑之經４’－二氟甲基取代之核苷衍生物
CN113874373A (zh)	2021-12-31	用于治疗乙型肝炎的治疗方法
CN105307661A (zh)	2016-02-03	4’-叠氮基,3’-脱氧基-3’-氟取代的核苷衍生物
WO2020243199A1 (en)	2020-12-03	Tricyclic compounds
CN116472063A (zh)	2023-07-21	包含经修饰的siRNA的靶向性偶联物
US11033556B2 (en)	2021-06-15	Bicyclic sulfonamides
CN114127082A (zh)	2022-03-01	作为sting调节剂的经修饰的环状二核苷化合物
Gao et al.	2016	l-Aspartic and l-glutamic acid ester-based ProTides of anticancer nucleosides: Synthesis and antitumoral evaluation
JP2020518657A (ja)	2020-06-25	多標的ヌクレオシド誘導体
JPH07508531A (ja)	1995-09-21	治療用ヌクレオシド
Tokarenko	2021	Novel modified nucleosides with antiviral or cytostatic activity
Kutz	2025	The Design and Synthesis of L-Nucleoside Reverse Fleximers

CN107250145A - 被取代的核苷、核苷酸及其类似物 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (3)

Publications (1)

Family

ID=56127561

Family Applications (1)

Country Status (12)

Cited By (2)

Families Citing this family (35)

Citations (5)

Family Cites Families (36)

Patent Citations (5)

Non-Patent Citations (2)

Cited By (2)

Also Published As

Similar Documents

Legal Events